for following the clinical course of the disease.
The laboratory tests in the second group do ilot reflect disease activity. In supplying information relative to streptococcal infection, they indicate whether the stage has been set for the development of rheunmatic fever. These aids include a throat culture for the presence of group A beta-hemolytic streptococci and the various streptococcal antibody tests (e.g., the ASO or antistreptolysin-O titer). These tests are nonspecific in the sense that they do niot differentiate in any clinically useful or conisistent way between those patients who do anid those patients who do inot develop rheumatic fever following streptococcal infections.' Nevertheless, wheii used with the clinical findings, these bacteriologic and immunologic tests help in determining whether the disease process is properly classified as acute rheumatic fever.
In patients with acnte rheumatic fever streptococcal antibody tests are in general a more reliable indicator of recent streptococcal inifection than throat cultures. At the time rheumatic fever is suspected, a routine throat culture is of rather limited value. Bv this time, the group A beta-hemolytic streptococei may have been eradicated by antibiotic therapy or, even without antibiotics, may be so reduced in number as to evade detection in a single routine culture. Therefore, a negative culture is of no significancye. Repeated throat cultures and cultures by special technics result in the demonstration of the infecting organism in a higher percentage of patients. 4 The great variety of antigenic products oi group A streptococei provides a rather wide indicators of recent streptocoecal infection. Those which have been studied most thoroughly following natural streptococcal infection in man include antibody responses to streptolysin 0, erythrogenic toxini, type-specific M protein, streptokinase, hyaluronidase, the desoxyribonucleases, and diphosphopyridine nucleotidase. With the exception of M protein, which is a surface component of the cell, these substances are extracellular products of the streptococcus, i.e., products released into the surrounding medium ( fig. 1 ). In addition to their antigenicity they are all biologically active. Indeed, it is largely by their biologic activity that they are known, since chemically pure preparations have not been obtained. Furthermore, specific antibody for each product is determined by neutralization of its specific biologic activity. In studying human infections antibodies to streptococcal substances other than those named have not proved satisfactory either beeause they are nonantigenic (streptolysin S, hyaluronic acid), poorly antigenic (proteinase, group-specific carbohydrate), nonspecific for Circulation, Volume XXI, April 1960 beta-hemolytic streptococei (nucleoprotein fraction), or poorly differentiated in unabsorbed sera (T protein, R protein, group-specific carbohydrate). Naturally occurring antibodies to other substances (ribonuclease, amylase, beta glueuronidase, lipoproteinase, and polyglycerophosphate) have not been extensively studied in human beings.5 Antibody to polyglycerophosphate is not likely to be useful in studying streptococcal infections in man because the antigen is present in a number of other gram-positive bacteria. 6 Earliest interest in streptococcal immunology quite naturally focused on those antibodies that neutralize streptococcal substances associated with the most striking clinical and laboratory manifestations of infection. Attention was drawn to antibody neutralizing the erythrogenic toxin of scarlet fever (antitoxin), to antibodies responsible for protection in experimental infectiois (antibodies to the M proteins), and to anitibodies inhibiting hemolytic substances produced by streptococvi (streptolysins).
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Antibodies to M Proteins (Type-Specific, Bactericidal, or Bacteriostatic Antibodies)
For some years immunity to streptococcal infections was in a state of confusion, confounded by a lack of knowledge of the antigenic composition of these organisms and by a preoccupation of many clinical investigators with scarlet fever and its antitoxin, which was subsequently shown to control the rash of scarlet fever but to afford no protection against invasion by streptococei.
The figure 2 . The slopes of the 3 lines representing these dilution methods vary considerably. The 2-fold system progresses to relatively high titers within a few dilutions, whereas the 1½/2-fold (Kaplan) method33 progresses more slowly and the 11/4-fold or 0.1 log (CARD)21 system shows even smaller increments. The design of the 2 other schemes results in titers that follow no constant mathematical sequence. The method of Hodge and Swift34 is by arithmetical progression, which changes at intervals. This method produces anl irregular curve, but has the advantage of resulting in nlumerical titers that are easy to remember. Although logarithmic in trend, the method of Raintz and Randall35 is irregular in progression and results in titers that are more difficult to remember. Despite these disadvanitages, this latter method is becoming imore and more widely used because it is often the scheme which accompanies the commercially available reagents.
Obviously, the spacing of increments in the particular scheme being used will influence to some extent both the percentage of patients showing an "aantibody response" and the "magnitude"' of these responses. For example, within the limits of reproducibility, anl antibody rise will be more frequently demonstrated by schemes with smaller increments.
Moreover, within any given schenme, the percentage of patients exhibiting an antibody rise will vary, depending upon the level of the initial antibody titer. Although some of the schemes are irregular, in general the arithmetic increments become progressively larger as one moves from the lower to the higher dilutions. Consequently, an antibody response is more likely to be demonstrated in patients with low initial titers than in patienits with high initial titers. To illustrate, with the 0.1-log increment system (CARD), a 100-unit rise in a patient whose initial titer is 63 units will result in a 4-tube increase, whereas an identical rise in a patient whose initial titer is 500 would not be detected (table 1) [36] [37] [38] [39] This may be due to a number of factors, including antibiotic therapy, age of the patient, high-initial antibody titers, inlfection with straiiis that are poor streptolysin-O producers, and dilution of the series with patients who by clinical or bacteriologic criteria appear to be infected with streptococei but whose current illness is indeed due to sonme other agent.
In adults, except those in situations where exposure to streptococcal infection is high, titers greater than 100 to 150 units may be considered uncommon.28 Adults who may be unusually exposed to streptococcal infection include those in the military services and mothers of school-age children.
In spite of the relative paucity of data on antistreptolysin-O titers in "normal" populations and in spite of some degree of overlapping of titers in "normal" and "rheumatic" populations ( 
Antihyaluronidase
Because of possible implications in the pathogenesis of rheumatic fever, a considerable flurry of interest followed the demonstration that group A streptococei produce an enzyme that depolymerizes hyaluronic acid, a constituent of synovial fluid and other conneetive tissues.55 This streptococcal enzyme is adaptively produced, i.e., production is stimulated by the addition of substrate to the culture medium.56 Only group A streptococei of types 4 and 22 produce appreciable amounts of the enzyme under in vitro conditions.57 The hyaluronidase of group A streptococci is immunologically distinct from the hyaluronidases from other sources (other groups of streptococei, other bacteria, mammalian tissues). 58, 59 This enzyme is inhibited by 2 factors present in human sera. The first, a nonspecific inhibitor (NSI) inhibits hyaluronidase-activity, regardless of the source of enzyme.60 It is heat-labile and requires magnesium ions for its action. This nonspecific inhibitor is an acute-phase reactant rather than an antibody; as such it develops early in infection, subsiding during convaleseence unless suppurative or nonsuppurative complications develop.2 The specific inhibitor (SI) is a true antibody, which develops several weeks after the onset of streptococcal infection, persists after the subsidence of inflammation, appears in the gamma-globulin fraction of serum, and neutralizes the hyaluronidase of group A streptococei specifically. It is heat-stable and does not require magnesium ions for its activation.2' 61 The in vitro determination of antihyaluronidase in human sera is based on the specifie inhibition of the capacity of streptococcal hyaluronidase to digest hyaluronic acid. Nonspecific inhibitor is inactivated by heating the sera at 56°C. for 30 minutes. 
